Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...

About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have ...

As use of GLP-1 weight loss drugs including Wegovy and Ozempic increases, brands are introducing new offerings.

Piper Sandler's Christopher Raymond joins 'Fast Money' to talk Amgen's stock sinking on GLP-1 results. Kamala Harris ...

According to CMS estimates, passage of the rule would open access to the weight-loss medications to 3.4 million potential new ...

CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs ...

GLP-1 medications like Ozempic and Wegovy are shielding the kidneys from harm, even as they help ease diabetes and obesity.

GLP-1 drugs such as Ozempic and Mounjaro have been heralded as some of the most important drug breakthroughs ever.

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.